First mRNA vaccine against deadly nipah virus shows promise in early trial
NCT ID NCT05398796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental mRNA vaccine (mRNA-1215) for Nipah virus, a deadly infection with no approved treatments. Forty healthy adults received two doses of the vaccine and were monitored for safety and immune response. The vaccine cannot cause Nipah infection. Results will help determine if further testing is warranted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NIPAH VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.